Ophthalmology
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial.
Arshad M Khanani, Carl J Danzig, Jeffrey S Heier, Glenn J Jaffe, Peter K Kaiser, David R Lally, Sunil S Patel, Lejla Vajzovic, Christina Y Weng, Hersh Patel, Julie Clark, Dhaval Desai, Don Luo, Erin Henry, Frank G Holz
Published: 202510.1016/j.ophtha.2025.12.011
Abstract
PURPOSE: Avacincaptad pegol (ACP) is a pegylated RNA aptamer that inhibits complement C5. The efficacy and safety of ACP 2mg was investigated in GATHER2, with positive Year 1 results published. Here, 2-year results are reported. DESIGN: Phase 3, 2-ye…
Preview only. Read the full abstract at the source